Gilead­'s cell ther­a­py busi­ness Kite cuts 7% of work­force

Gilead’s cell ther­a­py sub­sidiary Kite Phar­ma is let­ting go of rough­ly 300 em­ploy­ees, or about 7% of the unit’s staff.

“We are tak­ing mea­sures to fur­ther align our busi­ness for fu­ture growth, in­clud­ing stream­lin­ing some ar­eas of the or­ga­ni­za­tion to bet­ter op­ti­mize op­er­a­tional ef­fi­cien­cy,” a Gilead spokesper­son con­firmed in an emailed state­ment to End­points News.

In ad­di­tion to the cuts, it’s adding about 90 new jobs to the 4,000-plus-per­son group, mean­ing the net head­count re­duc­tion will be about 5%. Gilead did not re­spond to ques­tions on what as­pects of the cell ther­a­py busi­ness were pri­mar­i­ly im­pact­ed by the lay­offs.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER